Aigen Investment Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Aigen Investment Management’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-11,037	Closed	-$426K	–	836
2023 Q1	$426K	Buy	+11,037	New	+$454K	0.06%	347
2021 Q3	–	Sell	-4,963	Closed	-$342K	–	544
2021 Q2	$342K	Buy	+4,963	New	+$379K	0.06%	302
2020 Q4	–	Sell	-16,592	Closed	-$2.35M	–	873
2020 Q3	$2.35M	Buy	16,592 +9,148	+123%	+$1.53M	0.3%	87
2020 Q2	$1.47M	Buy	7,444 +5,861	+370%	+$1.21M	0.19%	157
2020 Q1	$310K	Buy	+1,583	New	+$341K	0.04%	576

Other funds holding LKFT

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

Aigen Investment Management's LKFT Position: Q2 2023 in Review

Aigen Investment Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2023, closing a stake of 11,037 shares — an estimated $426K sold.

Aigen Investment Management first reported a position in LKFT in Q1 2020 and held it in 5 quarters. The position peaked at $2.35M in Q3 2020. 76 funds tracked by Wall St. Rank hold LKFT as of Q2 2023.

Aigen Investment Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2023 after selling out during the quarter.
Aigen Investment Management sold 11,037 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2023, an estimated $426K.
Aigen Investment Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2020 and held it in 5 quarters.
Aigen Investment Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $2.35M in Q3 2020.
76 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2023.

Based on Aigen Investment Management's 13F filing for Q2 2023, filed 14 Aug 2023.